News

Kymriah gets NICE approval for DLBCL

06/02/2019

Author:

Graham Foxon, PhD, MBA
About the Author

Article Tags

NICE Oncology Pricing

Share this article

Related articles

Articles
10.08.2026
The Hidden Risk in Pharma Pricing: When Poor Gover...

Pricing strategies rarely fail because of one decision. More often, price potential is gradually ero...

Read more
Webinar
05.08.2026
Decoding Germany’s SHI reform practical impl...

Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 20...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch